Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey-Herng Sheu (Sheu WHH), Siew Pheng Chan (Chan SP), Bien J. Matawaran (Matawaran BJ), Chaicharn Deerochanawong (Deerochanawong C), Ambrish Mithal (Mithal A), Juliana Chan (Chan J), Ketut Suastika (Suastika K), Chin Meng Khoo (Khoo CM), Huu Man Nguyen (Nguyen HM), Ji Linong (Linong J), Andrea Luk (Luk A), Kun-Ho Yoon (Yoon KH)
Diabetes Metab J. 2020;44(1):11-32.   Published online 2020 Feb 21     DOI: https://doi.org/10.4093/dmj.2019.0208
Citations to this article as recorded by Crossref logo
The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea
Jong Eun Park, Seulgi Lee, Kirang Kim
BMC Geriatrics.2023;[Epub]     CrossRef
Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
Metabolism.2023; 138: 155311.     CrossRef
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Leili Gao, Zhifeng Cheng, Benli Su, Xiuhai Su, Weihong Song, Yushan Guo, Lin Liao, Xiaowen Chen, Jiarui Li, Xingrong Tan, Fangjiang Xu, Shuguang Pang, Kun Wang, Jun Ye, Yuan Wang, Lili Chen, Jingfang Sun, Linong Ji
Diabetes, Obesity and Metabolism.2023; 25(3): 785.     CrossRef
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, Molla Fahad, O'Brien Brendan, Santander Deion, Sudhakar Pemminati
Cureus.2023;[Epub]     CrossRef
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
Diabetes & Metabolism Journal.2023; 47(1): 82.     CrossRef
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, Zhiqi Wei, Ruya Zhang, Seema Malkani, Nilo B. Cater, Robert Frederich
Diabetes Therapy.2023; 14(2): 319.     CrossRef
Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
鸿 王
Advances in Clinical Medicine.2023; 13(02): 1667.     CrossRef
Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
Nephrology.2022; 27(2): 126.     CrossRef
Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, Irene Caruso, Nicola Marrano, Giuseppina Biondi, Rossella D’Oria, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
Journal of Diabetes Investigation.2022; 13(6): 986.     CrossRef
Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
Li-Li Shi, Ming Hao, Zhou-Yun Jin, Gui-Fang Peng, Ying-Ying Tang, Hong-Yu Kuang, Yaoyao Bian
Disease Markers.2022; 2022: 1.     CrossRef
Relationship Between Four Non-Insulin-Based Indexes of Insulin Resistance and Serum Uric Acid in Patients with Type 2 Diabetes: A Cross-Sectional Study
Rongfeng Han, Yang Zhang, Xia Jiang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1461.     CrossRef
The dual role of empagliflozin: Cardio renal protection in T2DM patients
Aimen Shafiq, Eman Mahboob, Muhammad Ammar Samad, Mohammad Hassam Ur Rehman, Zoaib Habib Tharwani
Annals of Medicine & Surgery.2022;[Epub]     CrossRef
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Katarzyna Wołos-Kłosowicz, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2022; 11(20): 6183.     CrossRef
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
Expert Opinion on Investigational Drugs.2021; 30(2): 85.     CrossRef
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
Diabetes, Obesity and Metabolism.2021; 23(8): 1754.     CrossRef
How do you treat obesity in the elderly pharmacologically?
Claudio Daniel González, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy.2021; 22(13): 1639.     CrossRef
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
Frontiers in Endocrinology.2021;[Epub]     CrossRef
New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Frontiers in Medicine.2021;[Epub]     CrossRef
Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
Diabetes Research and Clinical Practice.2021; 180: 109067.     CrossRef
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Mariana Tilinca, Robert Tiuca, Ioan Tilea, Andreea Varga
Journal of Personalized Medicine.2021; 11(12): 1249.     CrossRef
Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
Wayne H‐H Sheu
Journal of Diabetes Investigation.2020; 11(5): 1115.     CrossRef

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

André J Scheen
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765.     CrossRef
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases.2020; 8(2): 14.     CrossRef
Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis ― An Update on Recent Findings ―
Kimie Tanaka, Daiju Fukuda, Masataka Sata
Circulation Journal.2020; 85(1): 2.     CrossRef